Details for New Drug Application (NDA): 062664
✉ Email this page to a colleague
NDA 062664 describes NEOMYCIN AND POLYMYXIN B SULFATE, which is a drug marketed by Watson Labs, Xgen Pharms, Bausch And Lomb, Padagis Us, Sciegen Pharms Inc, Alcon Pharms Ltd, Ipharm, Nordic Pharma, Amring Pharms, and Sandoz, and is included in twenty-one NDAs. It is available from one supplier. Additional details are available on the NEOMYCIN AND POLYMYXIN B SULFATE profile page.
The generic ingredient in NEOMYCIN AND POLYMYXIN B SULFATE is bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate profile page.
The generic ingredient in NEOMYCIN AND POLYMYXIN B SULFATE is bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate. There are twenty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the bacitracin zinc; hydrocortisone; neomycin sulfate; polymyxin b sulfate profile page.
Summary for 062664
| Tradename: | NEOMYCIN AND POLYMYXIN B SULFATE |
| Applicant: | Watson Labs |
| Ingredient: | neomycin sulfate; polymyxin b sulfate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;IRRIGATION | Strength | EQ 40MG BASE/ML;200,000 UNITS/ML | ||||
| Approval Date: | Apr 8, 1986 | TE: | AT | RLD: | No | ||||
Complete Access Available with Subscription
